| Name | Solifenacin |
| Description | Solifenacin (YM905 free base) (YM905 free base) is a novel muscarinic receptor antagonist, its pKis for M1, M2 and M3 receptors is of 7.6, 6.9 and 8.0, respectively. |
| In vivo | Solifenacin exerts minimal inhibitory effects on salivary and cardiac responses at a dosage of 630 nmol/kg (0.3 mg/kg), achieving inhibition levels of 66% and 49%, respectively, at 2100 nmol/kg (1 mg/kg). At lower doses (63 and 210 nmol/kg or 0.03 and 0.1 mg/kg), Solifenacin slightly enhances saliva secretion. Conversely, it reduces bladder responses by 40% at 210 nmol/kg (0.1 mg/kg) and completely suppresses them at 2100 nmol/kg (1 mg/kg). Intravenously administered, Solifenacin (0.01 to 0.3 mg/kg) progressively augments bladder capacity and the volume of urine voided when dosed at 0.03 mg/kg or higher, without impacting residual volume or micturition pressure at any administered dosage. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/mL (151.74 mM), Sonication is recommended.
H2O : < 0.1 mg/mL (insoluble)
|
| Keywords | Muscarinic acetylcholine receptor | Solifenacin | YM905 | mAChR | YM 905 | Inhibitor | inhibit | YM-905 |
| Inhibitors Related | Adiphenine hydrochloride | Nanofin | Arecoline hydrobromide | Forskolin | CLOZAPINE N-OXIDE | Pilocarpine nitrate | Ribavirin | Adenine | Choline chloride | Propoxur |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Approved Drug Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Orally Active Compound Library | Bioactive Compounds Library Max |
United States
